Patent: 8,900,583
✉ Email this page to a colleague
Summary for Patent: 8,900,583
| Title: | Methods for treatment of brain injury utilizing biologics |
| Abstract: | A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonists include TNF receptor fusion proteins, TNF monoclonal antibodies (mAbs), humanized TNF mAbs, fully human TNF mAbs, chimeric TNF mAbs, domain TNF antibodies, mAB fragments, anti-TNF nanobodies, dominant negative TNF constructs and TNF inhibitory single chain antibody fragments. One of the preferred embodiments of this invention is the perispinal administration of etanercept for treatment of mammals following stroke. The use of Trendelenburg positioning, catheters, pumps, or depot formulations are included. |
| Inventor(s): | Tobinick; Edward Lewis (Boca Raton, FL) |
| Assignee: | TACT IP LLC (Boca Raton, FL) |
| Application Number: | 13/848,044 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,900,583
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2030-11-01 |
| Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2030-11-01 |
| Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2030-11-01 |
| Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2030-11-01 |
| Immunex Corporation | ENBREL MINI | etanercept | Injection | 103795 | 09/14/2017 | ⤷ Try a Trial | 2030-11-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
